b'<?xml version="1.0" ?>\n<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2019//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_190101.dtd">\n<PubmedArticleSet>\n<PubmedArticle>\n    <MedlineCitation Status="MEDLINE" Owner="NLM">\n        <PMID Version="1">31053403</PMID>\n        <DateCompleted>\n            <Year>2019</Year>\n            <Month>08</Month>\n            <Day>26</Day>\n        </DateCompleted>\n        <DateRevised>\n            <Year>2020</Year>\n            <Month>07</Month>\n            <Day>01</Day>\n        </DateRevised>\n        <Article PubModel="Print-Electronic">\n            <Journal>\n                <ISSN IssnType="Electronic">1095-6859</ISSN>\n                <JournalIssue CitedMedium="Internet">\n                    <Volume>154</Volume>\n                    <Issue>1</Issue>\n                    <PubDate>\n                        <Year>2019</Year>\n                        <Month>07</Month>\n                    </PubDate>\n                </JournalIssue>\n                <Title>Gynecologic oncology</Title>\n                <ISOAbbreviation>Gynecol. Oncol.</ISOAbbreviation>\n            </Journal>\n            <ArticleTitle>Nuclear receptor 4A1 (NR4A1) antagonists induce ROS-dependent inhibition of mTOR signaling in endometrial cancer.</ArticleTitle>\n            <Pagination>\n                <MedlinePgn>218-227</MedlinePgn>\n            </Pagination>\n            <ELocationID EIdType="pii" ValidYN="Y">S0090-8258(19)31180-1</ELocationID>\n            <ELocationID EIdType="doi" ValidYN="Y">10.1016/j.ygyno.2019.04.678</ELocationID>\n            <Abstract>\n                <AbstractText Label="OBJECTIVES">NR4A1 is overexpressed in many solid tumors, and the objectives of this study were to investigate the expression and functional role of this receptor in endometrial cancer cells and demonstrate that NR4A1 antagonist inhibit mTOR.</AbstractText>\n                <AbstractText Label="METHODS">Ishikawa and Hec-1B endometrial cells were used as models to investigate the parallel effects of NR4A1 knockdown by RNA interference (siNR4A1) and treatment with bis-indole-derived NR4A1 ligands (antagonists) on cell growth and survival by determining cell numbers and effects on Annexin V staining. Western blot analysis of whole cell lysates was used to determine effects of these treatments on expression of growth promoting, survival and apoptotic genes and mTOR signaling. Effects of NR4A1 antagonists on tumor growth were determined in athymic nude mice bearing Hec-1B cells as xenografts.</AbstractText>\n                <AbstractText Label="RESULTS">siNR4A1 or treatment with bis-indole-derived NR4A1 antagonists inhibited growth of endometrial cancer cells in vitro and endometrial tumors in vivo and this was accompanied by decreased expression of growth promoting and survival genes and mTOR inhibition.</AbstractText>\n                <AbstractText Label="CONCLUSIONS">NR4A1 exhibited pro-oncogenic activity in endometrial cells due, in part, to regulation of cell growth, survival and mTOR signaling, and all of these pathways and their associated gene products were inhibited after treatment with bis-indole-derived NR4A1 antagonists. Moreover, these compounds also blocked endometrial tumor growth in vivo demonstrating that NR4A1 is a potential novel drug target for treatment of endometrial cancer.</AbstractText>\n                <CopyrightInformation>Copyright \xc2\xa9 2019 Elsevier Inc. All rights reserved.</CopyrightInformation>\n            </Abstract>\n            <AuthorList CompleteYN="Y">\n                <Author ValidYN="Y">\n                    <LastName>Mohankumar</LastName>\n                    <ForeName>Kumaravel</ForeName>\n                    <Initials>K</Initials>\n                    <AffiliationInfo>\n                        <Affiliation>Department of Veterinary Physiology and Pharmacology, Texas AM University, College Station, TX 77843, USA.</Affiliation>\n                    </AffiliationInfo>\n                </Author>\n                <Author ValidYN="Y">\n                    <LastName>Li</LastName>\n                    <ForeName>Xi</ForeName>\n                    <Initials>X</Initials>\n                    <AffiliationInfo>\n                        <Affiliation>Department of Veterinary Physiology and Pharmacology, Texas AM University, College Station, TX 77843, USA.</Affiliation>\n                    </AffiliationInfo>\n                </Author>\n                <Author ValidYN="Y">\n                    <LastName>Sridharan</LastName>\n                    <ForeName>Subhashree</ForeName>\n                    <Initials>S</Initials>\n                    <AffiliationInfo>\n                        <Affiliation>Department of Medical Physiology, College of Medicine, Texas AM University, College Station, TX 77843, USA.</Affiliation>\n                    </AffiliationInfo>\n                </Author>\n                <Author ValidYN="Y">\n                    <LastName>Karki</LastName>\n                    <ForeName>Keshav</ForeName>\n                    <Initials>K</Initials>\n                    <AffiliationInfo>\n                        <Affiliation>Department of Veterinary Physiology and Pharmacology, Texas AM University, College Station, TX 77843, USA.</Affiliation>\n                    </AffiliationInfo>\n                </Author>\n                <Author ValidYN="Y">\n                    <LastName>Safe</LastName>\n                    <ForeName>Stephen</ForeName>\n                    <Initials>S</Initials>\n                    <AffiliationInfo>\n                        <Affiliation>Department of Veterinary Physiology and Pharmacology, Texas AM University, College Station, TX 77843, USA. Electronic address: ssafe@cvm.tamu.edu.</Affiliation>\n                    </AffiliationInfo>\n                </Author>\n            </AuthorList>\n            <Language>eng</Language>\n            <GrantList CompleteYN="Y">\n                <Grant>\n                    <GrantID>P30 ES023512</GrantID>\n                    <Acronym>ES</Acronym>\n                    <Agency>NIEHS NIH HHS</Agency>\n                    <Country>United States</Country>\n                </Grant>\n                <Grant>\n                    <GrantID>P30 ES029067</GrantID>\n                    <Acronym>ES</Acronym>\n                    <Agency>NIEHS NIH HHS</Agency>\n                    <Country>United States</Country>\n                </Grant>\n                <Grant>\n                    <GrantID>T32 ES026568</GrantID>\n                    <Acronym>ES</Acronym>\n                    <Agency>NIEHS NIH HHS</Agency>\n                    <Country>United States</Country>\n                </Grant>\n            </GrantList>\n            <PublicationTypeList>\n                <PublicationType UI="D016428">Journal Article</PublicationType>\n                <PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType>\n                <PublicationType UI="D013485">Research Support, Non-U.S. Gov\'t</PublicationType>\n            </PublicationTypeList>\n            <ArticleDate DateType="Electronic">\n                <Year>2019</Year>\n                <Month>04</Month>\n                <Day>30</Day>\n            </ArticleDate>\n        </Article>\n        <MedlineJournalInfo>\n            <Country>United States</Country>\n            <MedlineTA>Gynecol Oncol</MedlineTA>\n            <NlmUniqueID>0365304</NlmUniqueID>\n            <ISSNLinking>0090-8258</ISSNLinking>\n        </MedlineJournalInfo>\n        <ChemicalList>\n            <Chemical>\n                <RegistryNumber>0</RegistryNumber>\n                <NameOfSubstance UI="D007211">Indoles</NameOfSubstance>\n            </Chemical>\n            <Chemical>\n                <RegistryNumber>0</RegistryNumber>\n                <NameOfSubstance UI="D008024">Ligands</NameOfSubstance>\n            </Chemical>\n            <Chemical>\n                <RegistryNumber>0</RegistryNumber>\n                <NameOfSubstance UI="C539821">NR4A1 protein, human</NameOfSubstance>\n            </Chemical>\n            <Chemical>\n                <RegistryNumber>0</RegistryNumber>\n                <NameOfSubstance UI="D057105">Nuclear Receptor Subfamily 4, Group A, Member 1</NameOfSubstance>\n            </Chemical>\n            <Chemical>\n                <RegistryNumber>0</RegistryNumber>\n                <NameOfSubstance UI="D017382">Reactive Oxygen Species</NameOfSubstance>\n            </Chemical>\n            <Chemical>\n                <RegistryNumber>EC 2.7.1.1</RegistryNumber>\n                <NameOfSubstance UI="C546842">MTOR protein, human</NameOfSubstance>\n            </Chemical>\n            <Chemical>\n                <RegistryNumber>EC 2.7.1.1</RegistryNumber>\n                <NameOfSubstance UI="D058570">TOR Serine-Threonine Kinases</NameOfSubstance>\n            </Chemical>\n        </ChemicalList>\n        <MeshHeadingList>\n            <MeshHeading>\n                <DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName>\n            </MeshHeading>\n            <MeshHeading>\n                <DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName>\n            </MeshHeading>\n            <MeshHeading>\n                <DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName>\n            </MeshHeading>\n            <MeshHeading>\n                <DescriptorName UI="D017209" MajorTopicYN="N">Apoptosis</DescriptorName>\n                <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>\n            </MeshHeading>\n            <MeshHeading>\n                <DescriptorName UI="D045744" MajorTopicYN="N">Cell Line, Tumor</DescriptorName>\n            </MeshHeading>\n            <MeshHeading>\n                <DescriptorName UI="D016889" MajorTopicYN="N">Endometrial Neoplasms</DescriptorName>\n                <QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName>\n                <QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName>\n                <QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName>\n            </MeshHeading>\n            <MeshHeading>\n                <DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName>\n            </MeshHeading>\n            <MeshHeading>\n                <DescriptorName UI="D055785" MajorTopicYN="N">Gene Knockdown Techniques</DescriptorName>\n            </MeshHeading>\n            <MeshHeading>\n                <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>\n            </MeshHeading>\n            <MeshHeading>\n                <DescriptorName UI="D007211" MajorTopicYN="N">Indoles</DescriptorName>\n                <QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName>\n            </MeshHeading>\n            <MeshHeading>\n                <DescriptorName UI="D008024" MajorTopicYN="N">Ligands</DescriptorName>\n            </MeshHeading>\n            <MeshHeading>\n                <DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName>\n            </MeshHeading>\n            <MeshHeading>\n                <DescriptorName UI="D008819" MajorTopicYN="N">Mice, Nude</DescriptorName>\n            </MeshHeading>\n            <MeshHeading>\n                <DescriptorName UI="D057105" MajorTopicYN="N">Nuclear Receptor Subfamily 4, Group A, Member 1</DescriptorName>\n                <QualifierName UI="Q000037" MajorTopicYN="Y">antagonists &amp; inhibitors</QualifierName>\n                <QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>\n                <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>\n            </MeshHeading>\n            <MeshHeading>\n                <DescriptorName UI="D011897" MajorTopicYN="N">Random Allocation</DescriptorName>\n            </MeshHeading>\n            <MeshHeading>\n                <DescriptorName UI="D017382" MajorTopicYN="N">Reactive Oxygen Species</DescriptorName>\n                <QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName>\n            </MeshHeading>\n            <MeshHeading>\n                <DescriptorName UI="D015398" MajorTopicYN="N">Signal Transduction</DescriptorName>\n                <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>\n            </MeshHeading>\n            <MeshHeading>\n                <DescriptorName UI="D058570" MajorTopicYN="N">TOR Serine-Threonine Kinases</DescriptorName>\n                <QualifierName UI="Q000037" MajorTopicYN="Y">antagonists &amp; inhibitors</QualifierName>\n                <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>\n            </MeshHeading>\n            <MeshHeading>\n                <DescriptorName UI="D023041" MajorTopicYN="N">Xenograft Model Antitumor Assays</DescriptorName>\n            </MeshHeading>\n        </MeshHeadingList>\n        <KeywordList Owner="NOTNLM">\n            <Keyword MajorTopicYN="Y">NR4A1</Keyword>\n            <Keyword MajorTopicYN="Y">Pro-oncogenic antagonists</Keyword>\n            <Keyword MajorTopicYN="Y">mTOR inhibition</Keyword>\n        </KeywordList>\n    </MedlineCitation>\n    <PubmedData>\n        <History>\n            <PubMedPubDate PubStatus="received">\n                <Year>2019</Year>\n                <Month>01</Month>\n                <Day>10</Day>\n            </PubMedPubDate>\n            <PubMedPubDate PubStatus="revised">\n                <Year>2019</Year>\n                <Month>04</Month>\n                <Day>01</Day>\n            </PubMedPubDate>\n            <PubMedPubDate PubStatus="accepted">\n                <Year>2019</Year>\n                <Month>04</Month>\n                <Day>21</Day>\n            </PubMedPubDate>\n            <PubMedPubDate PubStatus="pubmed">\n                <Year>2019</Year>\n                <Month>5</Month>\n                <Day>6</Day>\n                <Hour>6</Hour>\n                <Minute>0</Minute>\n            </PubMedPubDate>\n            <PubMedPubDate PubStatus="medline">\n                <Year>2019</Year>\n                <Month>8</Month>\n                <Day>27</Day>\n                <Hour>6</Hour>\n                <Minute>0</Minute>\n            </PubMedPubDate>\n            <PubMedPubDate PubStatus="entrez">\n                <Year>2019</Year>\n                <Month>5</Month>\n                <Day>5</Day>\n                <Hour>6</Hour>\n                <Minute>0</Minute>\n            </PubMedPubDate>\n        </History>\n        <PublicationStatus>ppublish</PublicationStatus>\n        <ArticleIdList>\n            <ArticleId IdType="pubmed">31053403</ArticleId>\n            <ArticleId IdType="pii">S0090-8258(19)31180-1</ArticleId>\n            <ArticleId IdType="doi">10.1016/j.ygyno.2019.04.678</ArticleId>\n            <ArticleId IdType="pmc">PMC6625344</ArticleId>\n            <ArticleId IdType="mid">NIHMS1528277</ArticleId>\n        </ArticleIdList>\n        <ReferenceList>\n            <Reference>\n                <Citation>Carcinogenesis. 2014 Nov;35(11):2474-84</Citation>\n                <ArticleIdList>\n                    <ArticleId IdType="pubmed">25064356</ArticleId>\n                </ArticleIdList>\n            </Reference>\n            <Reference>\n                <Citation>Cancer. 2010 Dec 1;116(23):5415-9</Citation>\n                <ArticleIdList>\n                    <ArticleId IdType="pubmed">20681032</ArticleId>\n                </ArticleIdList>\n            </Reference>\n            <Reference>\n                <Citation>Oxid Med Cell Longev. 2017;2017:3296294</Citation>\n                <ArticleIdList>\n                    <ArticleId IdType="pubmed">28690762</ArticleId>\n                </ArticleIdList>\n            </Reference>\n            <Reference>\n                <Citation>Crit Rev Oncol Hematol. 2016 Dec;108:1-12</Citation>\n                <ArticleIdList>\n                    <ArticleId IdType="pubmed">27931828</ArticleId>\n                </ArticleIdList>\n            </Reference>\n            <Reference>\n                <Citation>CA Cancer J Clin. 2018 Jan;68(1):7-30</Citation>\n                <ArticleIdList>\n                    <ArticleId IdType="pubmed">29313949</ArticleId>\n                </ArticleIdList>\n            </Reference>\n            <Reference>\n                <Citation>PLoS One. 2015 Jun 02;10(6):e0128308</Citation>\n                <ArticleIdList>\n                    <ArticleId IdType="pubmed">26035713</ArticleId>\n                </ArticleIdList>\n            </Reference>\n            <Reference>\n                <Citation>Cancer. 2016 Sep 15;122(18):2787-98</Citation>\n                <ArticleIdList>\n                    <ArticleId IdType="pubmed">27308732</ArticleId>\n                </ArticleIdList>\n            </Reference>\n            <Reference>\n                <Citation>Histopathology. 2013 Jan;62(1):111-23</Citation>\n                <ArticleIdList>\n                    <ArticleId IdType="pubmed">23240673</ArticleId>\n                </ArticleIdList>\n            </Reference>\n            <Reference>\n                <Citation>Gut. 2012 May;61(5):714-24</Citation>\n                <ArticleIdList>\n                    <ArticleId IdType="pubmed">21873734</ArticleId>\n                </ArticleIdList>\n            </Reference>\n            <Reference>\n                <Citation>Curr Opin Obstet Gynecol. 2017 Feb;29(1):47-58</Citation>\n                <ArticleIdList>\n                    <ArticleId IdType="pubmed">27941361</ArticleId>\n                </ArticleIdList>\n            </Reference>\n            <Reference>\n                <Citation>Mol Endocrinol. 2010 Oct;24(10):1891-903</Citation>\n                <ArticleIdList>\n                    <ArticleId IdType="pubmed">20392876</ArticleId>\n                </ArticleIdList>\n            </Reference>\n            <Reference>\n                <Citation>Gynecol Oncol. 2018 Sep;150(3):569-580</Citation>\n                <ArticleIdList>\n                    <ArticleId IdType="pubmed">29843906</ArticleId>\n                </ArticleIdList>\n            </Reference>\n            <Reference>\n                <Citation>Free Radic Biol Med. 2015 Nov;88(Pt B):205-211</Citation>\n                <ArticleIdList>\n                    <ArticleId IdType="pubmed">26117317</ArticleId>\n                </ArticleIdList>\n            </Reference>\n            <Reference>\n                <Citation>Lancet Oncol. 2012 Aug;13(8):e353-61</Citation>\n                <ArticleIdList>\n                    <ArticleId IdType="pubmed">22846840</ArticleId>\n                </ArticleIdList>\n            </Reference>\n            <Reference>\n                <Citation>Mol Cancer Res. 2014 Apr;12(4):527-538</Citation>\n                <ArticleIdList>\n                    <ArticleId IdType="pubmed">24515801</ArticleId>\n                </ArticleIdList>\n            </Reference>\n            <Reference>\n                <Citation>J Natl Cancer Inst. 2018 Apr 1;110(4):354-361</Citation>\n                <ArticleIdList>\n                    <ArticleId IdType="pubmed">29045681</ArticleId>\n                </ArticleIdList>\n            </Reference>\n            <Reference>\n                <Citation>Cancer Cell. 2008 Oct 7;14(4):285-98</Citation>\n                <ArticleIdList>\n                    <ArticleId IdType="pubmed">18835031</ArticleId>\n                </ArticleIdList>\n            </Reference>\n            <Reference>\n                <Citation>Mol Cancer Ther. 2004 Mar;3(3):247-60</Citation>\n                <ArticleIdList>\n                    <ArticleId IdType="pubmed">15026545</ArticleId>\n                </ArticleIdList>\n            </Reference>\n            <Reference>\n                <Citation>Science. 2000 Aug 18;289(5482):1159-64</Citation>\n                <ArticleIdList>\n                    <ArticleId IdType="pubmed">10947977</ArticleId>\n                </ArticleIdList>\n            </Reference>\n            <Reference>\n                <Citation>Nucl Recept Signal. 2006;4:e002</Citation>\n                <ArticleIdList>\n                    <ArticleId IdType="pubmed">16604165</ArticleId>\n                </ArticleIdList>\n            </Reference>\n            <Reference>\n                <Citation>FASEB J. 2011 Jan;25(1):192-205</Citation>\n                <ArticleIdList>\n                    <ArticleId IdType="pubmed">20847229</ArticleId>\n                </ArticleIdList>\n            </Reference>\n            <Reference>\n                <Citation>Mol Endocrinol. 2014 Oct;28(10):1729-39</Citation>\n                <ArticleIdList>\n                    <ArticleId IdType="pubmed">25099012</ArticleId>\n                </ArticleIdList>\n            </Reference>\n            <Reference>\n                <Citation>Nat Commun. 2014 Mar 03;5:3388</Citation>\n                <ArticleIdList>\n                    <ArticleId IdType="pubmed">24584437</ArticleId>\n                </ArticleIdList>\n            </Reference>\n            <Reference>\n                <Citation>Endocr Relat Cancer. 2015 Oct;22(5):831-40</Citation>\n                <ArticleIdList>\n                    <ArticleId IdType="pubmed">26229035</ArticleId>\n                </ArticleIdList>\n            </Reference>\n            <Reference>\n                <Citation>Clin Cancer Res. 2011 May 15;17(10):3368-77</Citation>\n                <ArticleIdList>\n                    <ArticleId IdType="pubmed">21242118</ArticleId>\n                </ArticleIdList>\n            </Reference>\n            <Reference>\n                <Citation>Mod Pathol. 2015 Jun;28(6):836-44</Citation>\n                <ArticleIdList>\n                    <ArticleId IdType="pubmed">25720322</ArticleId>\n                </ArticleIdList>\n            </Reference>\n            <Reference>\n                <Citation>Oncotarget. 2016 May 24;7(21):31257-69</Citation>\n                <ArticleIdList>\n                    <ArticleId IdType="pubmed">27144436</ArticleId>\n                </ArticleIdList>\n            </Reference>\n            <Reference>\n                <Citation>Gynecol Oncol. 2017 Apr;145(1):200-207</Citation>\n                <ArticleIdList>\n                    <ArticleId IdType="pubmed">28040204</ArticleId>\n                </ArticleIdList>\n            </Reference>\n            <Reference>\n                <Citation>Cancer. 2016 Nov 15;122(22):3519-3528</Citation>\n                <ArticleIdList>\n                    <ArticleId IdType="pubmed">27603005</ArticleId>\n                </ArticleIdList>\n            </Reference>\n            <Reference>\n                <Citation>Histol Histopathol. 2006 May;21(5):533-40</Citation>\n                <ArticleIdList>\n                    <ArticleId IdType="pubmed">16493583</ArticleId>\n                </ArticleIdList>\n            </Reference>\n            <Reference>\n                <Citation>Cell. 2004 Feb 20;116(4):527-40</Citation>\n                <ArticleIdList>\n                    <ArticleId IdType="pubmed">14980220</ArticleId>\n                </ArticleIdList>\n            </Reference>\n            <Reference>\n                <Citation>Oncogene. 2012 Jul 5;31(27):3265-76</Citation>\n                <ArticleIdList>\n                    <ArticleId IdType="pubmed">22081070</ArticleId>\n                </ArticleIdList>\n            </Reference>\n            <Reference>\n                <Citation>Curr Oncol Rep. 2016 Apr;18(4):23</Citation>\n                <ArticleIdList>\n                    <ArticleId IdType="pubmed">26922329</ArticleId>\n                </ArticleIdList>\n            </Reference>\n            <Reference>\n                <Citation>Mol Endocrinol. 2014 Feb;28(2):157-72</Citation>\n                <ArticleIdList>\n                    <ArticleId IdType="pubmed">24295738</ArticleId>\n                </ArticleIdList>\n            </Reference>\n            <Reference>\n                <Citation>Endocrinology. 2018 May 1;159(5):1950-1963</Citation>\n                <ArticleIdList>\n                    <ArticleId IdType="pubmed">29635345</ArticleId>\n                </ArticleIdList>\n            </Reference>\n            <Reference>\n                <Citation>Nature. 2013 May 2;497(7447):67-73</Citation>\n                <ArticleIdList>\n                    <ArticleId IdType="pubmed">23636398</ArticleId>\n                </ArticleIdList>\n            </Reference>\n            <Reference>\n                <Citation>Cancer Res. 2010 Sep 1;70(17):6824-36</Citation>\n                <ArticleIdList>\n                    <ArticleId IdType="pubmed">20660371</ArticleId>\n                </ArticleIdList>\n            </Reference>\n            <Reference>\n                <Citation>Br J Cancer. 2015 Jul 14;113(2):299-310</Citation>\n                <ArticleIdList>\n                    <ArticleId IdType="pubmed">26172027</ArticleId>\n                </ArticleIdList>\n            </Reference>\n            <Reference>\n                <Citation>Gynecol Oncol. 2014 May;133(2):375-81</Citation>\n                <ArticleIdList>\n                    <ArticleId IdType="pubmed">24556063</ArticleId>\n                </ArticleIdList>\n            </Reference>\n        </ReferenceList>\n    </PubmedData>\n</PubmedArticle>\n\n</PubmedArticleSet>'